Not estimable in the model [BE/BA News]

posted by ElMaestro  – Denmark, 2017-03-14 11:41  – Posting: # 17155
Views: 15,390

Hi,

» Sorry, but I did not catch the idea. Should I try this model: Group+Patient(Sequence)+Sequence+Period+Treatment?

Yes try that with type I. I think type III may give the same as before if you are not using SAS.


» One more comment: the groups are unbalanced. Type I is suiatable for balanced groups as I undertood. Looks like I could not use the Type I model.

Your CI will be the same. Type I vs Type III is generally a topic that is of a much more sensitive nature to some people than e.g.religion or venereal diseases. People who grew up with SAS stick to type III, and type III only, because that is all they know and therefore they seem to be resistant to common sense. Besides, SAS invented the term "Least Squares Means" and that sounds so good that no reasonable alternative could ever exist, right?

Type I is not better or worse than type III. LS Means are no better than model effects. Depending on contrasts, model effects are LS Means and vice versa. And so forth...

if (3) 4

x=c("Foo", "Bar")
b=data.frame(x)
typeof(b[,1]) ##aha, integer?
b[,1]+1 ##then let me add 1


Best regards,
ElMaestro

“(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures.” New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,475 posts in 4,131 threads, 1,333 registered users;
online 5 (1 registered, 4 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 11:18 UTC

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5